Transcell Oncologics (www.transcellonco.science), an ASPIRE-TBI incubatee at the University of Hyderabad (UoH), announced a tie-up and on-boarding of GenepoweRx, a bioinformatics engine, in their workflow on 9th November 2021. Transcell developed a vertical named HEMATO (www.hemato.global) into adult stem cell technology translation in imparting hematopoietic stem cell transplantation procedure. This tie-up enables Transcell to offer HEMATO’s PREGEN genomics medicine prescription for managing any diseases/s predisposition predicted. These next-gen in-silico tools integrated into the HEMATO workflow offer solutions to health-conscious families and families with disease history in making data-based informed decisions managing and caring for their health.
The solutions under HEMATO developed to offer client’s predictive and comprehensive stem cell omics signatures (PREGEN), cryo-archival of enriched progenitors for tandem and transplantations (HEMATOCRYO), cell therapies in approved hematopoietic stem cell transplantation procedures (HSCT) are value additions in treating diseases supporting transplant specialists in personalizing the treatments.
GenepoweRx, developed by Dr Kalyan Uppaluri and Dr Hima Challa, Hyderabad based Genomics Medicine practising clinicians with training received from Stanford and Harvard University’s respectively, is endorsed by Memorial Sloan Kettering Cancer Centre (NY) to support personalizing targeted drug therapy strategies. K & H, a bespoke conceptual clinic, is run by them, offering a personalized plan for each of their patients, distilled from their world-class unmatched experience, practising genomic medicine.
“With our eye evenly on working in technology prop up to the intended client in benefiting from the regulated clinical practices, this working relationship with the Genomics medicine practitioners brings together innovation and execution personalizing technology to provide superior productized services,” said Subhadra Dravida Ph.D., CEO and Founder of Transcell in a joint statement along with Dr. Vinayender Tulla, Director, Transcell.
“By pairing bioinformatics tools, the relevant downstream clinical practice expertise with Transcell’s validated cell technology, we are excited to support their differentiated and meaningful offerings,” said Dr Kalyan Uppalurisigning, the working relationship here at Hyderabad.